Friday, June 9, 2023

ASCO23 Day 4 (6/5/23) Gyn Cancer Posters, Poster Discussion session & Misc topics

Note: Due to the number of Tweets embedded in this post the page may take some time to load.  

Monday's sessions included the Gyn Cancer Poster session and the Poster Discussion session. There were a few other sessions that I found interesting and are included at the end of this post. 

Poster Discussion Session

Initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC). ABSTRACT 5515
 
Randomized phase 2 study of gemcitabine with or without ATR inhibitor berzosertib in platinum-resistant ovarian cancer: Final overall survival (OS) and biomarker analyses. ABSTRACT 5512
"Gemcitabine/berzosertib did not significantly improve OS versus gemcitabine alone. Pts with PFI≤3 months and pts with RS-low tumors may derive a survival advantage from addition of berzosertib to gemcitabine in the platinum-resistant setting. Clinical trial information: NCT02595892."
 
Correlation of cyclin E1 expression and clinical outcomes in a phase 1b dose-escalation study of azenosertib (ZN-c3), a WEE1 inhibitor, in combination with chemotherapy (CT) in patients (pts) with platinum-resistant or refractory (R/R) epithelial ovarian, peritoneal, or fallopian tube cancer (EOC). ABSTRACT 5513
"Study assessed azenosertib + paclitaxel (PAC), carboplatin (Carbo), gemcitabine (GEM), or pegylated liposomal doxorubicin (PLD) in pts with metastatic high-grade serous EOC after ≤2 lines of chemotherapy. Patients with Cyclin E1 overexperessing tumors, a subgroup with suboptimal benefits from chemo , demonstrated significant imporovements in ORR and PFS vs patients with tumors having low expresssion."

 
A phase II trial of palbociclib combined to letrozole after progression on second-line chemotherapy for women with ER/PR-positive high-grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer: LACOG 1018.  ABSTRACT 5541
"Palbociclib combined to letrozole demonstrated a significant efficacy in terms of PFS rate at 12 weeks (63.4%) and CBR (71.8%), with no new safety concerns in women with recurrent advanced and metastatic hormone receptor-positive ovarian cancer. These results warrant further investigation of palbociclib plus letrozole in high-grade ovarian cancer."
The Normal Risk Ovarian Screening Study (NROSS): Twenty-one year update. ABSTRACT 5522
"A total of 7,856 healthy postmenopausal women were screened annually for a total of 50,596 women-years in a single arm study (NCT00539162). Serum CA125 was analyzed with the Risk of Ovarian Cancer Algorithm (ROCA) each year....An elevated ROCA, characterized by a significantly rising CA125, prompted referral of 2% of participants to transvaginal sonography (TVS) each year and required only 2 operations to detect each case of ovarian cancer, indicating that CA125 used in this way is adequately specific for effective screening.
Posters
Here are a few posters I found interesting that were not part of the discussion session. 

Efficacy and safety of niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer who had measurable residual disease: A post-hoc subgroup analysis of the PRIME study. ABSTRACT 5562

"This study aims to report the efficacy, including antitumor activity, and safety of niraparib maintenance therapy in patients with measurable residual disease MRD after first-line platinum-based chemotherapy1LCT from the phase 3 PRIME trial. ...  Median PFS (95% CI) was 22.3 (8.7–not estimable) months with niraparib versus 8.3 (5.6–11.0) months with placebo (hazard ratio, 0.36; 95% CI, 0.19–0.71)."


Circulating tumor DNA (ctDNA) as a marker of residual disease and recurrence in resected stage I-IV epithelial ovarian cancer (EOC). ABSTRACT 5553
ctDNA detection after ovarian cancer cytoreduction identifies pts at very high risk of recurrence. Pts with BRCA mutations were more likely to have negative ctDNA post-op. The role of ctDNA in guiding neoadjuvant and adjuvant therapy to improve outcomes, warrants further investigation. Clinical trial information: ACTRN12617001119381.
 

Safety and efficacy of PIPAC in ovarian cancer patients with peritoneal metastases: A first-in-US phase I study.  ABSTRACT 5554

"Pressurized intraperitoneal aerosolized chemotherapy (PIPAC) is a novel IP drug delivery method that optimizes tissue penetration depth and drug distribution, to treat recurrent peritoneal malignancies. 

PIPAC with cisplatin/doxorubicin in platinum-resistant ovarian cancer is well tolerated. Intraperitoneal responses were seen in a subset of low-grade serous ovarian cancer patients, which may warrant further study."



 

Miscellaneous ASCO topics: 

Patient Centered Research

Solid tumor research

Destiny Pan-Tumor-02
Her-2 expressing tumors -trastuzumab deruxtecan (T-DXd)

 

This brings my highlights from the ASCO 2023 Annual meeting to a close. I hope to see everyone in person next year!

 Dee

Every Day is a Blessing ! 

Posted by at
Labels: , , , , , , , , , , , ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)